ArticlePloS one2013
An ultra high-throughput, whole-animal screen for small molecule modulators of a specific genetic pathway in Caenorhabditis elegans.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Drug screens using the nematode Caenorhabditis elegans.Genetics · 2025Review
- A High-Throughput Behavioral Assay for Screening Novel Anxiolytics in Larval Zebrafish.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Machine learning-based analysis of microfluidic device immobilized C. elegans for automated developmental toxicity testing.Scientific reports · 2025Article
- vivoBodySeg: Machine learning-based analysis of C. elegans immobilized in vivoChip for automated developmental toxicity testing.Research square · 2024Article
- Chemical Genetics inACS chemical biology · 2024Article
- Quantifying the fitness effects of resistance alleles with and without anthelmintic selection pressure using Caenorhabditis elegans.PLoS pathogens · 2024Article
- High-throughput light sheet imaging of adult and larvalRSC advances · 2024Article
- Phenotypic screening models for rapid diagnosis of genetic variants and discovery of personalized therapeutics.Molecular aspects of medicine · 2023Review
- Variation in anthelmintic responses are driven by genetic differences among diverse C. elegans wild strains.PLoS pathogens · 2023Article
- Article
- A new use for old drugs: identifying compounds with an anti-obesity effect using a high through-put semi-automatedHeliyon · 2022Article
- Neurotoxicity Evaluation of Nanomaterials Using C. elegans: Survival, Locomotion Behaviors, and Oxidative Stress.Current protocols · 2022Article
- Article
- Investigation of anthelmintic activity of the acetone extract and constituents of Typha capensis against animal parasitic Haemonchus contortus and free-living Caenorhabditis elegans.Parasitology research · 2021Article
- Drug discovery: Insights from the invertebrate Caenorhabditis elegans.Pharmacology research & perspectives · 2021Review
- Ligninolytic activity of thePeerJ · 2021Article
- Parallel-Channel Electrotaxis and Neuron Screening ofMicromachines · 2020Article
- A robust and miniaturized screening platform to study natural products affecting metabolism and survival in Caenorhabditis elegans.Scientific reports · 2020Article
- Article
- Digging deeper: methodologies for high-content phenotyping in Caenorhabditis elegans.Lab animal · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
High-throughput screening (HTS) is a powerful approach to drug discovery, but many lead compounds are found to be unsuitable for use in vivo after initial screening. Screening in small animals like C. elegans can help avoid these problems, but this system has been limited to screens with low-throughput or no specific molecular target. We report the first in vivo 1536-well plate assay for a specific genetic pathway in C. elegans. Our assay measures induction of a gene regulated by SKN-1, a master regulator of detoxification genes. SKN-1 inhibitors will be used to study and potentially reverse multidrug resistance in parasitic nematodes. Screens of two small commercial libraries and the full Molecular Libraries Small Molecule Repository (MLSMR) of ∼364,000 compounds validate our platform for ultra HTS. Our platform overcomes current limitations of many whole-animal screens and can be widely adopted for other inducible genetic pathways in nematodes and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.